Moving from suppressing symptoms to inoculating the brain against trauma

Health · Published 14 October 2026 Swipe more like this →

In short: Most antidepressants are designed to manage depression once it has already taken hold. But a new frontier in psychopharmacology aims to do something radical: prevent mental illness from developing in the first place by fortifying the body's natural resilience to stress.

Current psychiatric treatments, such as SSRIs, primarily function by suppressing symptoms rather than addressing underlying causes or preventing onset. A major void remains within medical science, especially regarding depression and PTSD—which the WHO identifies as the primary global cause of disability. Neuroscientist Rebecca Brachman is working to shift this paradigm toward preventative psychopharmacology. Pharmaceutical research has historically focused almost exclusively on fine-tuning existing medications rather than seeking preventative methods. This shift is significant because current drugs do not cure the underlying conditions.

Brachman’s discovery occurred accidentally while she was conducting baseline tests on mice using an emerging rapid-acting antidepressant. She noticed that a specific group of mice remained happy and social even when exposed to stressors that typically induce depression. This led to the identification of a new class of drugs designed to protect against the detrimental effects of both acute and chronic stress, potentially allowing individuals to recover and grow from traumatic experiences rather than being sidelined by them. Brachman first verified that her initial compound had no persistent effects on memory or movement before testing for stress resilience. Her team now aims to create prophylactic compounds that fortify natural biological defenses against trauma.

Parallel research at UC Davis is exploring another frontier: creating 'psychedelic-like' compounds that target brain plasticity without the hallucinogenic side effects. By using UV light to convert amino acids into new chemical scaffolds, researchers have identified molecules that activate 5-HT2A serotonin receptors—key targets for treating PTSD and addiction—while avoiding the intense perceptual alterations of traditional psychedelics. The UC Davis team combined tryptamine with various amino acids to generate these novel molecules. They used computer modeling to screen 100 different compounds for their interaction strength with specific brain receptors.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• Moving from suppressing symptoms to inoculating the mind against trauma
• The accidental discovery that might prevent mental disorders before they start
• The complex reality of how antidepressants actually function
• How a failed antipsychotic became the world's first tricyclic antidepressant
• The complex architecture of depression management and its many layers
• The brain's famous 'speech centre' is not quite what the textbooks say.
• 2021: A Paradigm Shift in Our Understanding of the Human Brain
• Could a molecule from Gila monster saliva silence the noise of addiction?
• The biological architecture that powers every thought and movement
• Can you consciously rewire your brain to stop loving someone?
• Why low serotonin levels don't tell the whole story of depression
• Can we rewrite the past to heal the present?

More in Neuroscience · More in Health · Latest · A–Z · All topics